Press Releases

Apr 21, 2022, 07:30 ET Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin’s compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongoing – data expected 4Q 2022 CRANBURY, N.J., April 21, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) […]

Discuss Ongoing PL9643 Pivotal Phase 3 Clinical Trial Webinar Monday, March 7th at 10:30 AM ET Mar 03, 2022, 07:30 ET CRANBURY, N.J., March 3, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today

– Initiated Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Expected Second Half Calendar 2022 – Approximately $47.3 Million in Cash and Cash Equivalents at December 31, 2021 – Projected Cash Runway through March 31, 2023 – Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis

Feb 10, 2022, 07:30 ET CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

Pre-clinical data demonstrate positive treatment effects of melanocortins for ulcerative colitis Genomic data characterizing the mechanism of action Jan 21, 2022, 07:30 ET CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system,

Jan 07, 2022, 10:59 ET CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference

Top-Line Results Currently Expected Second Half Calendar 2022 Dec 28, 2021, 07:30 ET CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical

Potential Broad Utility in Treating Indications Characterized by Cytokine Storm Nov 30, 2021, 07:30 ET CRANBURY, N.J., Nov. 30, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that the U.S. Patent and

— Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022 — Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start First Half Calendar 2022 with Top-Line Results Expected in the Second

Nov 10, 2021, 16:30 ET CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management